SLC5A2 and partial lipodystrophy: A retrospective review of the medical records (N = 22 for safety and N = 12 for efficacy) of patients with partial lipodystrophy treated with SGLT2 inhibitors (canagliflozin, empagliflozin, and dapagliflozin) showed promising results [79].